We created a way to help cancer centers demonstrate collaboration for CCSG application and renewal. Product Manager, Jeremy Shapiro, explains our process for finding a solution.
Indiana University Melvin and Bren Simon Cancer Center sees 52% time savings with Forte Participant Payments
With an increasing number of clinical trials conducted each year, IU’s Simon Cancer Center searched for a system that would decrease clinical staff’s time spent paying study participants and reduce inefficient workflows and associated costs.
Karmanos Cancer Institute unites operational teams and creates optimized processes with Forte Insights for OnCore
Team members at the Barbara Ann Karmanos Cancer Institute recognized the importance of operational efficiency, and investigated ways they could gather and present operational data they had already collected to identify areas of success and opportunities for growth.
Learn how to use data to achieve your 2018 research goals and inform future operational decisions.
Learn the telltale signs that it’s time for your research site to consider outside help for protocol calendar builds.
Hear our expert panelists discuss their predictions for clinical research in the coming year. Discover insights on centralization of research operations, the push for more electronic solutions, adapting to changes in national standards, the growing complexity of modern trials, and much more.
See the results of Forte’s survey of over 120 representatives from clinical trial sites and sponsors on the causes and challenges of extremely delayed clinical trial payments.
Learn how sites can quantify protocol complexity and anticipate resources to ensure more efficient clinical trial processes.
Principal Investigators are responsible for the compliant and efficient execution of a clinical trial. How can a research organization empower investigators with the tools and information to maximize their success?
Workshop discussion reveals common struggles and creative solutions for communicating with PIs about site financials.